Introduction to Cognition Therapeutics
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a dynamic clinical-stage biopharmaceutical company committed to discovering and developing groundbreaking therapeutics. These efforts are especially focused on combating neurodegenerative disorders that significantly impact individuals and families worldwide.
Participation in the Roth Healthcare Opportunities Conference
Recently, Cognition announced that its president and CEO, Lisa Ricciardi, will be sharing insights and expertise at the 3rd Annual Roth Healthcare Opportunities Conference. Slated for October 9, she will participate in a panel discussion titled Frontiers in Neuroscience.
Panel Discussion Highlights
During this significant conference, Ricciardi will delve into the latest advancements in neuroscience and highlight the potential of Cognition's lead candidate, CT1812. This novel drug is aimed at treating Alzheimer's disease, as well as other related cognitive disorders.
One-on-One Investor Meetings
Ricciardi is also scheduled to host one-on-one investor meetings. In these sessions, she plans to showcase recent successes and developments related to CT1812, the company’s lead therapeutic candidate. Cognition aims to engage with investors who are interested in the ongoing advancements and opportunities within the company.
Recent Innovations
Cognition Therapeutics continues to strive for innovative approaches in treating age-related conditions. Their lead candidate, CT1812, has shown promise in early clinical trials for Alzheimer’s disease and dementia with Lewy bodies. Furthermore, the company is exploring potential treatments for dry age-related macular degeneration, demonstrating a commitment to enhancing quality of life for numerous patients.
Commitment to Research and Development
The company's widespread investigations into small molecule therapeutics aim to address the various pathways that become impaired in degenerative diseases. This strategic focus enables Cognition to identify and regulate physiological pathways distinct from traditional treatment methodologies.
Pipeline and Future Goals
With a robust pipeline of ?-2 receptor modulators, Cognition believes in its approach to tackle age-related deteriorations effectively. The company continues to push boundaries in scientific research, aiming to bring groundbreaking therapies to market.
Contact Information
For those interested in learning more about Cognition Therapeutics or wishing to engage with the company, contact details are provided:
Cognition Therapeutics, Inc.
Email: info@cogrx.com
Media Contact: Casey McDonald
Tiberend Strategic Advisors, Inc.
Email: cmcdonald@tiberend.com
Investor Contact: Mike Moyer
LifeSci Advisors
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is Cognition Therapeutics focusing on at the conference?
Cognition Therapeutics is showcasing its advancements in neuroscience and discussing its lead candidate, CT1812, for treating neurodegenerative diseases.
Who will represent Cognition Therapeutics at the event?
Lisa Ricciardi, the president and CEO, will represent Cognition Therapeutics at the Roth Healthcare Opportunities Conference.
What is CT1812?
CT1812 is Cognition's leading therapeutic candidate being developed to treat Alzheimer's disease and related cognitive disorders.
How can investors schedule meetings with Cognition?
Investors interested in one-on-one meetings with Cognition's team should contact their Roth Capital Partners' sales representative for registration.
What types of conditions is Cognition Therapeutics targeting?
The company is focusing on neurodegenerative disorders, particularly Alzheimer’s disease and dry age-related macular degeneration.